Endoscopy International Open

The updated Asia-Pacific consensus statement on the role of endoscopic management in malignant hilar biliary obstruction.

Phonthep Angsuwatcharakon, Santi Kulpatcharapong, Alan Chuncharunee, Christopher Khor, Benedict Devereaux, Jong Ho Moon, Thawee Ratanachu-ek, Hsiu P Wang, Nonthalee Pausawasdi, Amit Maydeo, Takao Itoi, Ryan Ponnudurai, Mohan Ramchandani, Yousuke Nakai, Dong Wan Seo, Takeshi Ogura, Raymond S Tang, Pradermchai Kongkam, Dadang Makmun, Frederick Dy, Wiriya-porn Ridtitid, Yu T Kuo, Khanh C Pham, Borathchakra Oung, Jeffrey Lee, Rungsun Rerknimitr.

Affiliations below.

DOI: 10.1055/a-2366-7302


Conflict of Interest: The authors declare that they have no conflict of interest.

Abstract: The first Asia–Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma were published in 2013. Since then, new evidence on the role of endoscopy for management of malignant hilar biliary obstruction (MHBO) has emerged. To update the recommendation, we reviewed the literature using a PICO (population/intervention/comparison/outcomes) framework and created consensus statements. The expert panel voted anonymously using the modified Delphi method, and all final statements were evaluated for the quality of evidence and strength of recommendation. The important points with inadequate supporting evidence were classified as key concepts. There were 7 statements and 5 key concepts that reached consensus. The statements and key concepts dealt with multiple aspects of endoscopy-based management in MHBO starting from diagnosis, strategies and options for biliary drainage, management of recurrent biliary obstruction, management of cholecystitis after biliary stenting, and adjunctive treatment before stenting. Although the recommendations may assist physicians in planning the treatment for MHBO patients, they should not replace the decision of a multidisciplinary team in the management of individual patients.

Corresponding Author: Prof. Rungsun Rerknimitr, Chulalongkorn University, Department of Medicine, 2nd floor, Bhumisiri Bldg. King Chulalongkorn Memorial Hospital, 10330 Bangkok, Thailand, cholangiogram@gmail.com, ercp@live.com

Affiliations:
Phonthep Angsuwatcharakon, King Chulalongkorn Memorial Hospital, Internal medicine, Bangkok, Thailand
Santi Kulpatcharapong, King Chulalongkorn Memorial Hospital, Medicine, Bangkok, Thailand
Alan Chuncharunee, Mahidol University Faculty of Medicine Ramathibodi Hospital, Medicine, Bangkok, Thailand
[...]
Rungsun Rerknimitr, Chulalongkorn University, Department of Medicine, Bangkok, Thailand
Introduction

The management of malignant hilar biliary obstruction (MHBO) is challenging not only from diagnosis, due to the limited sensitivity of current available diagnostic tools,[1] but also in terms of management, due to the complexity of the biliary anatomy. Endoscopy has a major role to play in managing MHBO as it is less invasive than the other modalities. The first Asia Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma published in 2013[2] aimed to assist the clinician in managing this condition. However, the body of knowledge has evolved significantly, and new evidence has emerged, especially regarding the role of endoscopy including endoscopic ultrasonography (EUS) and cholangioscopy. Therefore, the Asia Pacific working group on hepatobiliary cancer concluded that the consensus statements needed to be updated based on the current evidence and experience.

Methods

The consensus statements were developed using the GRADE framework.[3, 4] The planning team (PA, SK, and AC) set clinical questions based on the population, intervention, comparison, and outcomes (PICO) outline. The evidence relevant to each question was independently searched by 2 of the planning team from 3 databases (Medline, EMBASE, and Cochrane) and additional evidence from the references was manually searched. Then, the statements were drafted. The level of evidence was graded according to the international GRADE system.[4, 5] A modified Delphi method was used to establish the consensus.[6] In brief, two rounds of anonymous electronic voting system were undertaken. The expert panel was
presented with the evidence and asked to rate their opinion on each statement as A: accept completely, B: accept with some reservation, C: accept with major reservation, D: reject with some reservation, or E: reject completely. A statement would achieve consensus when over 80% of the responses were “accept completely” or “accept with minor revision”. On the other hand, a statement would be refuted when over 80% of respondents voted to “reject completely” or “reject with some reservation”. There were 24 experts in hepatobiliary endoscopy including gastroenterologists and surgeons from 14 countries in the Asia-Pacific region who participated in this consensus. All statements were edited and finally agreed at the on-line meeting session. The important points which currently have inadequate supporting evidence were classified as key concepts. Finally, 7 statements and 5 key concepts reached consensus. All statements and key concepts were finally concluded after presentation for public consultation at Asian Pacific Digestive Week 2023, Bangkok, Thailand. The roles of endoscopy in the management of MHBO were conceptualized in figure 1.

**Statements**

Statement 1: In patients with suspected malignant hilar obstruction for which ERCP is indicated, a combination of intraductal biopsy and cytology should be performed at the index ERCP, to confirm the etiology.

Quality of evidence: high

Level of agreement: A; 100%, B; 0%, C; 0%, D; 0%, E; 0%
While the majority of biliary strictures having malignant etiology,[7] tissue diagnosis is still required and remains challenging to confirm due to limited sensitivity of standard tissue acquisition methods. Two of the most used and widely available endoscopic retrograde cholangiopancreatography (ERCP)-based diagnostic techniques are brush cytology and intraductal biopsy, however their sensitivity is low at only 21-56% and 43-67%, respectively.[8, 9] Data from a meta-analysis revealed that by combining these two methods the sensitivity increases to 70%.[9] A combination of both methods at index ERCP is recommended to achieve the highest yield of malignancy.

Newer technologies have been reported to improve the diagnosis of MHBO, and these include cholangioscopy and molecular techniques. Cholangioscopy provides direct visualization and targeted biopsy of the bile duct, which have sensitivity and specificity of up to 93% and 82%, respectively.[10] The utility of cholangioscopy at the first ERCP or after negative tissue acquisition is debatable. Additional fluorescence in situ hybridization (FISH) on the cytology sample significantly improved the sensitivity for diagnosis of malignant biliary stricture; 55% vs 38%, respectively (p = 0.001).[11] Furthermore, newer DNA-based molecular diagnostic techniques such as next generation sequencing, using tissue from either brushing or biopsy, showed promising results with an increase in the sensitivity for diagnosis of malignant biliary stricture up to 83-96% [12, 13]. However, the availability and cost-effectiveness of these technologies are major limitations.

Statement 2: Preoperative biliary drainage can be performed if clinically indicated; however, this should be balanced with the risk of infection.
In patients with resectable hilar cholangiocarcinoma, the role of pre-operative biliary drainage is debatable. Two meta-analyses showed no difference in mortality between patients with or without preoperative biliary drainage (PBD).[14, 15] However, PBD was associated with higher morbidity due to infectious complications, in unselected cases.[14, 15] In patients with total bilirubin of 15 mg/dL or more though, PBD did not increase morbidity.[15] It is noteworthy that when strict criteria including cholangitis, prolonged jaundice, or delayed surgery (e.g. waiting for portal vein intervention to induce hypertrophy of future remnant liver segments, malnutrition [serum albumin less than 3 g/dL], etc.) were applied, the PBD group showed lower major morbidity when compared with patients without PBD (OR = 0.51; 95% CI; 0.18–1.42). [14]

Statement 3: For palliation of unresectable malignant hilar biliary obstruction, the selection of segments to drain and the number of stents used is dependent on the Bismuth classification and the liver volume to be drained, with the aim of decompressing more than 50% of viable liver. 

Quality of evidence: moderate

Level of agreement: A; 83%, B; 17%, C; 0%, D; 0%, E; 0%
Vienne, et al.[16] reported a retrospective study in 2010 which demonstrated that drainage of >50% of liver volume was associated with better drainage effectiveness, longer survival, and less cholangitis when compared to <50% drainage. According to this study, the liver was grossly divided into 3 major sectors including the right anterior, right posterior, and left sectors. Each sector accounted for 30% of liver volume and the remaining segments I and IV accounted for 10%. An atrophic segment, if present, was considered a non-viable segment. This approach can guide segment selection and the number of stents to be placed. For example, without an atrophic segment, in Bismuth type I-II disease (with a stent inserted in the right lobe, and draining both anterior and posterior sectors), a single stent could drain >50% of viable liver volume. On the other hand, in Bismuth type III-IV, 2 or more stents may be required to obtain >50% drainage (Figure 2). In addition, the benefit of a higher percentage of liver drainage was reported in another retrospective study from Caillol, et al. in 2019.[17] Maximum drainage of greater than 80% of viable liver volume drainage was associated with longer survival when compared to less than 80% drainage (Hazard ratio [HR] = 2.46; 95% CI: 1.16-5.23, p = 0.02).

Statement 4: To reduce the risk of post-ERCP cholangitis, hepatic segment stenting can be performed employing wire-guided intrahepatic duct selection with pre-defined MRCP and/or MDCT. Air/carbon dioxide cholangiogram may be used to confirm correct guidewire location and if contrast injection is deemed necessary, complete biliary drainage of injected ducts is recommended.

Quality of evidence: moderate

Level of agreement: A; 74%, B; 22%, C; 4%, D; 0%, E; 0%
Hilar biliary obstruction is an independent risk factor for post-ERCP cholangitis.[18-20] In MHBO, contrast injection without adequate drainage of the injected segments led to cholangitis and diminished patient survival.[21] Careful evaluation and planning for drainage of preselected segment(s) by magnetic resonance cholangiopancreatography (MRCP) and/or multidetector computed tomography (MDCT) is necessary before ERCP. During ERCP, guidewire selection of the desired segment under fluoroscopic guidance should be the initial step. Any injection (contrast media, air, or carbon dioxide [CO\textsubscript{2}]) below the stricture may result in contamination of the unplanned segment(s). After guidewire placement into the pre-selected duct, with a good alignment of the wire course, a catheter can be passed over the guidewire into the desired segment. Bile should be aspirated to decompress the segment.[22] Two small randomized controlled trials (RCTs) have confirmed that to ensure correct location of the catheter, an air or CO\textsubscript{2} cholangiogram reduces the risk of cholangitis without diminishing technical and clinical success rates.[22, 23] However, if an air or CO\textsubscript{2} cholangiogram is insufficient to provide clear anatomical delineation, an injection of the lowest possible volume of contrast media may be performed. Complete or near complete drainage of those injected ducts during the procedure is required to prevent cholangitis.

Statement 5: After failed multi-segmental drainage by metallic stenting in complex malignant hilar obstruction, either percutaneous or EUS-guided biliary drainage of undrained liver segment can be performed.

Quality of evidence: low
The percutaneous approach is an option for additional biliary drainage after inadequate drainage by ERCP as undrained segments on either side of the liver can be selectively targeted. However, the key drawbacks of percutaneous drainage include patient discomfort, external loss of bile content and volume, and recurrent biliary obstruction (RBO). Recent advances in therapeutic EUS make internal drainage of the undrained biliary segment possible, and this may be considered an alternative to percutaneous approach. (Figure 3)

An open-labelled study with historical controls compared a combination of endoscopic drainage by ERCP and EUS with percutaneous drainage in patients with unresectable bismuth III or IV MHBO, who had good performance status and an expected life expectancy greater than 3 months.[24] The technical success (84% vs 100%), clinical success (79% vs 77%), and complication rates (26% vs 35%) were not different between the endoscopy and percutaneous groups, respectively. Interestingly, the endoscopy group had a significantly lower rate of recurrent RBO at 3 months (27% vs 88%) and 6 months (22% vs 100%) compared to the percutaneous group. In addition, there was a trend toward longer median time to RBO in the endoscopy group compared to the percutaneous group (92 vs 40 days, respectively; p=0.06). Therefore, EUS-guided biliary drainage represents an alternative to percutaneous approaches after inadequate biliary drainage by ERCP.

Statement 6: For trans-papillary drainage of Bismuth II-IV, in the patient who may respond well to systemic chemotherapy multiple plastic stenting with scheduled stent exchange may be
preferred over metallic stenting. However, metallic stenting by either side-by-side or stent-in-
stent approach should be considered in the patient who is not a candidate for or who has failed
systemic chemotherapy.

Quality of evidence: moderate

Level of agreement: A; 57%, B; 35%, C; 4%, D; 0%, E; 4%

Stent options for trans-papillary biliary drainage consist of plastic stents (PS) and self-
expandable metal stents (SEMS). PS have a smaller diameter when compared to SEMS, which
are associated with shorter stent patency. In the subgroup of hilar obstruction reported in a meta-
analysis in 2015 (800 patients from 6 studies),[25] SEMS had lower therapeutic failure (odds
ratio [OR] 0.28; 95% CI, 0.13-0.63), 30-day occlusion rate (OR 0.16; 95% CI, 0.04-0.62), long-
term occlusion rate (OR 0.28; 95% CI, 0.19-0.39), and cholangitis (OR 0.30; 95% CI, 0.12-0.74)
when compared with PS. However, 30-day mortality (OR 0.62; 95% CI, 0.30-1.31) and
reintervention per patient (mean difference, 0.34; 95% CI, 0.78 to 0.11) were not different
between SEMS and PS. In 2021, Xia et al.[26] reported a propensity-matched, retrospective
study of 356 patients comparing 4 approaches to biliary drainage in MHBO consisting of
bilateral SEMS, unilateral SEMS, bilateral PS, and unilateral PS. Approximately one third of
patients in all groups received adjuvant treatments (e.g. chemotherapy, radiotherapy, and
immunotherapy). The bilateral SEMS group had the highest, statistically significant clinical
success rate (98.9%), the lowest incidence of postprocedural cholangitis (8%), and the longest
stent patency (9.6 months) when compared with the other 3 approaches. Furthermore, bilateral
SEMS drainage was associated with fewer total interventions (1.2 ± 0.5 interventions) and longer
overall survival (7.1 months) when compared with unilateral or bilateral PS. Kim et al.[27] retrospectively compared palliative treatment with bilateral SEMS and multiple PS in MHBO due to cholangiocarcinoma in 102 patients. Only a tenth of patients received adjuvant therapy, and the median survival was about 9 months. This study showed that multiple plastic stents had higher cholangitis risk (HR, 2.08; 95%CI, 1.21-3.58) and were associated with higher 6-month mortality (HR, 2.91; 95% CI, 1.26-6.71) than bilateral SEMS.

As a result of advances in systemic treatment of MHBO including chemotherapy, immunotherapy, and targeted therapy, patients’ survival may exceed the patency of uncovered SEMS which is not removable.[28, 29] Therefore, concerns of complications from uncovered SEMS have been raised in this population. In 2023, Al Nakshabandiet al.[30] reported a retrospective, 25-year tertiary cancer center experience of 333 patients with MHBO from cholangiocarcinoma. Approximately half of patients had received adjuvant treatment. The study showed that although SEMS had higher clinical success, this was countered by higher stent-specific complication rate including migration, occlusion, ingrowth, and overgrowth with OR of 4.85 (95% CI, 3.23-7.27). PS may be superior to SEMS in terms of removability and stent revision in MHBO in patients who respond to adjuvant therapy. Although a fully covered SEMS (FCSEMS) is removable, FCSEMS might occlude segmental bile ducts when placed across the liver hilum and evidence for placing bilateral FCSEMS in MHBO is awaiting.

SEMSs can be placed across the hilum either in side-by-side or stent-in-stent fashion. Lee et al.[31] reported a randomized study comparing these 2 techniques and showed no difference in technical and clinical success rates, stent patency, and survival. In 2022, Cao et al.[32] reported a meta-analysis of 315 MHBO patients from 6 studies comparing these 2 techniques of SEMSs insertion. There was no significant difference between the two groups in terms of clinical success
(OR: 1.07; 95% CI: 0.46-2.49, p=0.87), complications (risk difference: 0.12; 95% CI: -0.04-0.27, p=0.15), stent dysfunction (OR: 0.68; 95% CI: 0.42-1.10, p=0.11), and overall survival (HR: 0.97; 95% CI: 0.82-1.16, p=0.74).

Statement 7: ERCP is the preferred option for revision of recurrent biliary obstruction after transpapillary placement of uncovered metallic stent(s). For inaccessible segments, or following previous stent-in-stent insertion, EUS-guided or percutaneous drainage are the preferred rescue procedures.

Quality of evidence: low
Level of agreement: A; 93%, B; 7%, C; 0%, D; 0%, E; 0%

Options for the management of recurrent biliary obstructions after placement of transpapillary metal stents include transpapillary insertion of a PS or another SEMS, and percutaneous transhepatic biliary drainage (PTBD). Ridtitid et al.[33] compared the outcomes of second interventions for occluded metallic stents. In a subgroup of 13 patients with MHBO, the reinterventions were PS (6 patients), SEMS (3 patients), and PTBD (4 patients). The median stent patency was 60, 60, and 90 days, and median survival was 130, 215, and 185 days in the PS, SEMS, and PTBD groups respectively, but the difference did not reach statistical significance. Okuno et al.[34] reported an 80.7% technical success rate of repeat transpapillary reintervention in 31 patients with MHBO who had prior stent-in-stent, dual SEMS placement. Technical failure was recorded in 6 patients as only one SEMS could be placed due to the guidewire did not traverse the mesh of the first stent, thus preventing successful second SEMS
placement. All these patients were successfully drained by a percutaneous approach. Kitamura et al.[35] reported endoscopic reintervention in 49 patients who previously had 2 or more SEMSs placed across the hilum; 27 patients had side-by-side and 22 patients had stent-in-stent SEMS placement. Transpapillary re-intervention by ERCP had a technical success rate of 69.4%. In the 15 patients who failed ERCP drainage, and subsequent EUS-guided reintervention was successful in 13 patients (86.7%). Two patients who failed EUS-guided reintervention were successfully drained by a percutaneous approach.

Key concepts

Key concept 1: Palliative biliary drainage may not be beneficial in patients with poor performance status who have short life expectancy and should be avoided.

Level of agreement: A; 58%, B; 42%, C; 0%, D; 0%, E; 0%

Almost two-thirds of patients with malignant hilar biliary obstruction are not amendable to curative surgical resection at the time of diagnosis.[36] These individuals may be treated with systemic therapy including chemotherapy, immunotherapy, and radiation. Palliative biliary drainage in inoperable MHBO provides several benefits, especially in several situations, including reducing hyperbilirubinemia in patients intended for systemic therapy, alleviating pruritus, or minimizing infective adverse events such as cholangitis.[37] The route of biliary drainage mainly includes percutaneous and endoscopic approaches. These two strategies are not different in 30-day mortality rate and overall adverse events.[38, 39] Adverse events associated with biliary drainage include cholangitis, RBO, cholecystitis, pancreatitis, tumor seeding, and diminished quality of life due to external drainage tubes.[38, 39] Unfortunately, palliative biliary
drainage in patients with poor performance status does not alter survival outcomes or quality of life. Robson et al.[40] reported a cohort study of 109 patients with unresectable malignant biliary obstruction comparing PTBD and conservative treatment. There was no difference in the quality of life in patients with post-procedure survival of fewer than five months. The negative impact of poor prognostic disease outweighed the benefit of the procedure. In addition, palliative biliary drainage in patients with high baseline American Society of Anesthesiologists grade (HR 6.47, 95% CI; 2.02–20.74), or low serum albumin (HR 1.23, 95% CI; 1.05–1.43) was associated with increased in-hospital mortality following drainage. The primary causes of mortality included biliary sepsis and renal failure. The presence of pre-procedural biliary sepsis was a major contributor to both morbidity and mortality.[41] Careful patient selection for palliative biliary drainage is therefore crucial and requires discussing the risks and benefits among the multidisciplinary team, patient, and caregivers. Risk prediction of clinical success after endoscopic biliary stenting may be a tool for making individualized decisions.[42, 43]

Key concept 2: If additional transmural EUS-guided biliary drainage is required, a transgastric approach is recommended for the left hepatic lobe.

Level of agreement: A; 75%, B; 25%, C; 0%, D; 0%, E; 0%

EUS-guided transmural biliary drainage has continued to evolve over the past decade. For drainage of intrahepatic bile ducts, the transgastric or transduodenal approach can be considered according to their proximity to left lateral segments (segment II and III) and right posterior segments (segment VI and VII), respectively. However, transgastric drainage is a more
established technique in which specially designed accessories are available.[44] This contrasts with transduodenal drainage for which there are only a handful preliminary reports and specially designed equipment is lacking. Ogura et al.[45] reported a series of EUS-guided drainage of right hepatic duct obstruction in 11 patients with MHBO. The route of drainage was transgastric puncture of left hepatic duct and bridge to right hepatic duct in 7 patients (Figure 4), and transgastric puncture (at gastric antrum) of right hepatic duct in 3 patients, and transduodenal puncture in 1 patient. Technical and functional success was reported in all patients, without complication. Ma et al.[46] reported EUS-guided hepatoduodenostomy (HDS) with conventional FCSEMS in 35 patients with segregated right hepatic duct and failed drainage by ERCP. The technical and clinical success rates were 97% and 80%, respectively. However, adverse events were reported to be up to 20%. EUS-guided hepaticogastrostomy (HGS) may be performed via the segment II or III approach, depending on patient anatomy, selection of a puncture window without vascular interposition, guidewire manipulation skill, and endoscopists’ expertise. A recent retrospective multicenter study revealed no difference in technical success, functional success, and adverse events between puncture of segment II and III.[47] With EUS-HGS via segment II, the location of puncture site should be carefully selected such that access is made from the stomach rather than from the distal esophagus. If necessary, following left duct puncture, attempts to bridge the right intrahepatic duct via left intrahepatic duct from HGS access may be considered.

Key concept 3: For EUS-guided hepaticogastrostomy, either plastic or metallic stent can be chosen.

Level of agreement: A; 73%, B; 18%, C; 9%, D; 0%, E; 0%
Several specifically designed plastic and metallic stents have been introduced to reduce adverse events and improve outcomes of EUS-HGS. An 8-Fr single-pigtail plastic stent with a tapered proximal end, four internal flanges, and an effective length of 15 cm was reported with a 100% technical success rate and median stent patency of 4 months without serious adverse events.[48] Unfortunately, this stent is only available in Japan, and therefore a 7-Fr double-pigtail plastic stent may be an alternative option due to its widespread availability and affordability.[49] Shibuki et al. [50] retrospectively reviewed patients who underwent EUS-HGS. Their series documented 109 patients with plastic stent (7, 8, or 8.5 Fr) and 43 patients with FCSEMS. Technical success, overall survival and adverse events were not different between the two groups. However, the time to RBO was significantly longer in the FCSEMS than the PS group (646 vs 202 days, respectively). Hybrid metallic stents have been specially designed for HGS use. Their design features a combination of a proximal uncovered portion, to be placed in bile duct and hepatic parenchyma to avoid side branch obstruction, and a distal covered portion to be placed in gastric wall to prevent bile leakage. The covered portion is accountable for one-third to half of the stent which varies from 30 to 50 mm in length. The length of the covered part of the stent deployed inside the gastric cavity should be at least 20 mm to prevent stent migration into the peritoneum.[51-53]

Key concept 4: If acute cholecystitis develops after biliary metallic stenting, EUS-guided gallbladder decompression with or without permanent stenting of the gallbladder is an alternative to percutaneous cholecystostomy or surgery.
Acute cholecystitis is a potential complication that may occur after metallic stent placement for MHBO.[54] Reflux of duodenal contents, pressure effect on the cystic duct orifice from tumor mass, or the stent’s expansile force potentially contribute to acute cholecystitis.[55]

To manage this condition, gallbladder decompression is required to alleviate symptoms and provide source control of infection. EUS-guided gallbladder decompression is an alternative to the conventional percutaneous or surgical approaches.[56] EUS-guided gallbladder aspiration may be performed as the initial step, with the option of proceeding to transmural gallbladder drainage stent can be considered if cholecystitis persists or recurs.

Key concept 5: Photodynamic therapy or endobiliary radiofrequency ablation may be used as adjunctive treatment prior to plastic or metallic biliary stent placement to improve stent patency and patient survival.

The aim of photodynamic therapy (PDT) and endobiliary radiofrequency ablation (RFA) is to provide an additional local control of the tumor. Lu et al.[57] reported a meta-analysis in 2015 comparing PDT plus stent versus stent alone in patients with unresectable cholangiocarcinoma. Seven studies, including two RCTs were analyzed with most patients having hilar involvement. The meta-analysis showed that the PDT plus stent group had significantly longer survival than the stent alone group (HR = 0.49, 95% CI; 0.33-0.73, p=0.0005). Dolak et al.[58] reported in 2017 that SEMS placement was associated with longer stent patency than plastic stent after PDT (269 vs 62 days, respectively, p < 0.01). In 2016,
Schmidt et al. [59] reported in a retrospective study that RFA plus plastic stent was superior to PDT plus plastic stent in respect of premature stent dysfunction at 3 months (29% vs 65%, respectively, p<0.01). The main caution for patients undergoing PDT is that they need to avoid light exposure and stay in a darkened room for 3-4 days. PDT is associated with an incidence of phototoxic reaction in 11.11% [57].

Kang et al. [50] reported a RCT in 2022 comparing RFA plus bilateral PS and bilateral PS alone in 30 patients. The study showed that RFA significantly reduced premature PS occlusion within 3 months when compared with bilateral PS alone (30.8% vs 76.9% respectively, p = 0.018), while adverse events were not different between the 2 groups. Oh et al. [60] reported a retrospective study in 2022 comparing RFA plus SEMS and SEMS alone. This study showed that there was no difference in stent patency (140 vs 192 days, p= 0.41) and survival (311 vs 311 days, p= 0.73) between RFA plus SEMS and SEMS alone groups. Multivariate cox analysis showed that “not receiving chemotherapy” was an independent risk for stent occlusion while RFA had no significant effect on stent occlusion.

Conclusions

A decade on from the first Asia–Pacific consensus, biliary endoscopy techniques have undergone significant advancements, offering new diagnostic and therapeutic approaches for MHBO. These include the improvement of diagnostic sensitivity, efficacy, and safety of drainage procedures, and particularly the growing role of therapeutic EUS. However, successful management requires careful patient selection based on several factors including, but not limited to, clinical presentation, biliary anatomy, level of obstruction, and most importantly, the
availability of local expertise. A multidisciplinary approach remains crucial for optimal decision-making.
**Figure 1** Conceptualized roles of endoscopy in management of malignant hilar biliary obstruction.

MDCT; multidetector computed tomography, MRCP; magnetic resonance cholangiopancreatography, ERCP; endoscopic retrograde cholangiopancreatography, PTBD; percutaneous biliary drainage, EUS-BD; endoscopic ultrasound-guided biliary drainage, EUS-GBD; endoscopic ultrasound-guided gallbladder drainage, PTC; percutaneous cholecystostomy.

* Preoperative biliary drainage may be indicated in patients with cholangitis, prolonged jaundice, delayed surgery (e.g. waiting for portal vein intervention, malnutrition [serum albumin less than 3 g/dL], etc.), or total bilirubin ≥15 mg/dL.

** Wire-guided selection of preselected liver segment before performing cholangiogram. Followed by air/carbon dioxide cholangiogram or limited injection with contrast media. Photodynamic therapy or endo-biliary radiofrequency ablation may be used as adjunctive treatment before stenting.
Figure 2 Strategy for biliary sector selection for drainage according to Bismuth classification of malignant hilar biliary obstruction.

RA; right anterior sector, RP; right posterior sector, L; left sector.

a: Bismuth I: one stent can drain all three sectors (100%).

b: Bismuth II: placement of one stent in the right main hepatic duct can drain both RA and RP sectors (60%).

c: Bismuth IIIa: at least two stents are required to achieve at least 50% of liver volume.

d: Bismuth IIIb: placement of one stent in the right main hepatic duct can drain both RA and RP sectors (60%).

f: Bismuth IV: at least two stents are required to achieve at least 50% of liver volume.
Figure 3 Endoscopic ultrasound-guided biliary drainage of undrained liver segment after ERCP.

Endoscopic ultrasound-guided hepaticogastrostomy for drainage of the left hepatic sector after inadequate drainage of right hepatic sector by ERCP.
Figure 4 Transgastric approach of endoscopic ultrasound-guided drainage of right hepatic duct.

Endoscopic ultrasound-guided biliary drainage is a viable technique to bridge right and left hepatic duct via a transgastric puncture.
References


12. Arechederra M, Rullán M, Amat I et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022; 71: 1141-1151. DOI: 10.1136/gutjnl-2021-325178


47. Sekine M, Hashimoto Y, Shibuki T et al. A retrospective multicenter study comparing the punctures to B2 and B3 in endoscopic ultrasound-guided hepaticogastrostomy. DEN Open 2023; 3: e201. DOI: https://doi.org/10.1002/deo2.201
Suspect for hilar cholangiocarcinoma with available MDCT or MRCP

- Resectable?
  - Yes
  - ERCP** with intraductal biopsy and/or brush cytology and biliary stenting
  - Require for preoperative drainage?**
    - Yes
    - EUS-BD or PTBD
    - Follow-up
    - Achieved 50% of viable liver volume?
      - Yes
      - ERCP reintervention
      - No
      - EUS-GBD or PTC
  - No
  - Plastic stent
  - Non-responder
  - SEMS
  - EUS-BD or PTBD
  - Failed or inadequate

- No
  - Proceed to surgery

Best supportive care

- Poor performance status?
  - Yes
  - Non-responder
  - SEMS
  - Acute cholecystitis
  - No
  - EUS-GBD or PTC

(a) RA
(b) L
(c) RP
(d) L
(e) RA